HMG-CoA Reductase Inhibitors and Myotoxicity
- 1 January 2000
- journal article
- review article
- Published by Springer Nature in Drug Safety
- Vol. 22 (6) , 441-457
- https://doi.org/10.2165/00002018-200022060-00003
Abstract
The 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors specifically inhibit HMG-CoA reductase in the liver, thereby inhibiting the biosynthesis of cholesterol. These drugs...Keywords
This publication has 133 references indexed in Scilit:
- Primary Prevention of Coronary Heart DiseaseDrugs, 1997
- AtorvastatinDrugs, 1997
- Endothelial Dysfunction and Atherothrombotic Occlusive DiseaseDrugs, 1997
- Effect of Age and Gender on Pharmacokinetics of Atorvastatin in HumansThe Journal of Clinical Pharmacology, 1996
- Reduction of LDL Cholesterol by 25% to 60% in Patients With Primary Hypercholesterolemia by Atorvastatin, a New HMG-CoA Reductase InhibitorArteriosclerosis, Thrombosis, and Vascular Biology, 1995
- Cytosolic Ca2+ Increase and Cell Damage in L6 Rat Myoblasts by HMG-CoA Reductase InhibitorsBiochemical and Biophysical Research Communications, 1994
- Comparative Pharmacokinetics of Lovastatin, Simvastatin and Pravastatin in HumansThe Journal of Clinical Pharmacology, 1992
- High-Density Lipoprotein — The Clinical Implications of Recent StudiesNew England Journal of Medicine, 1989
- HMG-CoA Reductase Inhibitors for Treatment of HypercholesterolemiaNew England Journal of Medicine, 1988
- Helsinki Heart Study: Primary-Prevention Trial with Gemfibrozil in Middle-Aged Men with DyslipidemiaNew England Journal of Medicine, 1987